Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia
Dan Huang1, Yan Yang1, Jian Sun1, Xiaorong Dong1, Jiao Wang1, Hongchen Liu1, Chengquan Lu2, Xueyu Chen1, Jing Shao2(), Jinsong Yan1()
1. Dalian Key Laboratory of Hematology, Liaoning Hematopoeitic Stem Cell Transplantation Medical Center, Department of Hematology of the Second Hospital of Dalian Medical University, Dalian 116027, China 2. Dalian Key Laboratory of Hematology, Liaoning Hematopoeitic Stem Cell Transplantation Medical Center, Department of Environmental Health and Toxicology, School of Public Health, Dalian Medical University, Dalian 116044, China
Aberrant expression of annexin A2-S100A10 heterotetramer (AIIt) associated with PML/RARα fusion protein causes lethal hyperfibrinolysis in acute promyelocytic leukemia (APL), but the mechanism is unclear. To facilitate the investigation of regulatory association between ANXA2 and promyelocytic leukemia/retinoic acid receptor a (PML/RARα) fusion protein, this work was performed to determine the transcription start site of ANXA2 promoter with rapid amplification of 5′-cDNA ends analysis. Zinc-induced U937/PR9 cells expressed PML/RARα fusion protein, and resultant increases in ANXA2 transcripts and translational expressions of both ANXA2 and S100A10, while S100A10 transcripts remained constitutive. The transactivation of ANXA2 promoter by PML/RARα fusion protein was 3.29±0.13 fold higher than that by control pSG5 vector or wild-type RARα. The overexpression of ANXA2 in U937 transfected with full-length ANXA2 cDNA was associated with increased S100A10 subunit, although S100A10 transcripts remained constitutive. The tPA-dependent initial rate of plasmin generation (IRPG) in zinc-treated U937/PR9 increased by 2.13-fold, and cell invasiveness increased by 27.6%. Antibodies against ANXA2, S100A10, or combination of both all remarkably inhibited the IRPG and invasiveness in U937/PR9 and NB4. Treatment of zinc-induced U937/PR9 or circulating APL blasts with all-trans retinoic acid (ATRA) significantly reduced cell surface ANXA2 and S100A10 and associated reductions in IRPG and invasiveness. Thus, PML/RARα fusion protein transactivated the ANXA2 promoter to upregulate ANXA2 and accumulate S100A10. Increased AIIt promoted IRPG and invasiveness, both of which were partly abolished by antibodies against ANXA2 and S100A10 or by ATRA.
Melnick A, Licht JD. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93(10): 3167–3215
2
Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106(9): 3342–3347 https://doi.org/10.1073/pnas.0813280106
3
Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, Browett P, Grigg A, Firkin F, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012; 120(8): 1570–1580
4
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 2012; 97(2): 227–234 https://doi.org/10.3324/haematol.2011.047506
5
Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y, Liu X, Han X, Hu L, Wang S, Zhao Y, Zhang Y, Fan S, Lv C, Li L, Zhu L. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 2010; 115(9): 1697–1702 https://doi.org/10.1182/blood-2009-07-230805
6
Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy M, Mathews V. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 2009; 15(11): 1479–1484 https://doi.org/10.1016/j.bbmt.2009.07.010
7
Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, Rosenblat TL, Altman JK, Douer D, Rowe JM, Tallman MS. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118(5): 1248–1254 https://doi.org/10.1182/blood-2011-04-346437
8
Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, de Th Hé, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101(15): 5328–5335 https://doi.org/10.1073/pnas.0400053101
9
Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010; 28(24): 3866–3871 https://doi.org/10.1200/JCO.2010.28.5031
10
Liu YJ, Wu DP, Liang JY, Qiu HY, Jin ZM, Tang XW, Fu CC, Ma X. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Med Oncol 2011; 28(Suppl 1): S513–S521 https://doi.org/10.1007/s12032-010-9733-7
11
Avvisati G, Lo Coco F, Mandelli F. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin Hematol 2001; 38(1): 4–12 https://doi.org/10.1053/shem.2001.20861
12
Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156(1): 24–36 https://doi.org/10.1111/j.1365-2141.2011.08922.x
13
Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340(13): 994–1004 https://doi.org/10.1056/NEJM199904013401303
14
Yan J, Wang K, Dong L, Liu H, Chen W, Xi W, Ding Q, Kieffer N, Caen JP, Chen S, Chen Z, Xi X. PML/RARα fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association. Proc Natl Acad Sci USA 2010; 107(8): 3716–3721 https://doi.org/10.1073/pnas.0915006107
O’Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM. Regulation of S100A10 by the PML-RAR-α oncoprotein. Blood 2011; 117(15): 4095–4105 https://doi.org/10.1182/blood-2010-07-298851
17
Udalova IA, Kwiatkowski D. Interaction of AP-1 with a cluster of NF-κB binding elements in the huma n TNF promoter region. Biochem Biophys Res Commun 2001; 289(1): 25–33 https://doi.org/10.1006/bbrc.2001.5929
18
Meng YS, Khoury H, Dick JE, Minden MD. Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia 2005; 19(11): 1941–1947 https://doi.org/10.1038/sj.leu.2403836
19
Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11(5): 1475–1489 https://doi.org/10.1093/nar/11.5.1475
20
Surette AP, Madureira PA, Phipps KD, Miller VA, Svenningsson P, Waisman DM. Regulation of fibrinolysis by S100A10 in vivo. Blood 2011; 118(11): 3172–3181 https://doi.org/10.1182/blood-2011-05-353482
21
Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM, Falcone DJ, Hajjar KA. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004; 103(1): 317–324 https://doi.org/10.1182/blood-2003-04-1304
22
Kassam G, Choi KS, Ghuman J, Kang HM, Fitzpatrick SL, Zackson T, Zackson S, Toba M, Shinomiya A, Waisman DM. The role of annexin II tetramer in the activation of plasminogen. J Biol Chem 1998; 273(8): 4790–4799 https://doi.org/10.1074/jbc.273.8.4790
23
Olwill SA, McGlynn H, Gilmore WS, Alexander HD. Annexin II cell surface and mRNA expression in human acute myeloid leukaemia cell lines. Thromb Res 2005; 115(1–2): 109–114 https://doi.org/10.1016/j.thromres.2004.07.014
24
Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein. Blood 1998; 92(7): 2244–2251
25
Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci 2013; 14(3): 6259–6305 https://doi.org/10.3390/ijms14036259
26
Moreau K, Ghislat G, Hochfeld W, Renna M, Zavodszky E, Runwal G, Puri C, Lee S, Siddiqi F, Menzies FM, Ravikumar B, Rubinsztein DC. Transcriptional regulation of Annexin A2 promotes starvation-induced autophagy. Nat Commun 2015; 6: 8045 https://doi.org/10.1038/ncomms9045
27
Huang B, Deora AB, He KL, Chen K, Sui G, Jacovina AT, Almeida D, Hong P, Burgman P, Hajjar KA. Hypoxia-inducible factor-1 drives annexin A2 system-mediated perivascular fibrin clearance in oxygen-induced retinopathy in mice. Blood 2011; 118(10): 2918–2929 https://doi.org/10.1182/blood-2011-03-341214
28
Madureira PA, Surette AP, Phipps KD, Taboski MAS, Miller VA, Waisman DM. The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood 2011; 118(18): 4789–4797 https://doi.org/10.1182/blood-2011-06-334672
29
Sharma MC, Sharma M. The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 2007; 13(35): 3568–3575 https://doi.org/10.2174/138161207782794167
30
Hou Y, Yang L, Mou M, Hou Y, Zhang A, Pan N, Qiang R, Wei L, Zhang N. Annexin A2 regulates the levels of plasmin, S100A10 and Fascin in L5178Y cells. Cancer Invest 2008; 26(8): 809–815 https://doi.org/10.1080/07357900801898664
31
He KL, Deora AB, Xiong H, Ling Q, Weksler BB, Niesvizky R, Hajjar KA. Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. J Biol Chem 2008; 283(28): 19192–19200 https://doi.org/10.1074/jbc.M800100200
32
Nazmi AR, Ozorowski G, Pejic M, Whitelegge JP, Gerke V, Luecke H. N-terminal acetylation of annexin A2 is required for S100A10 binding. Biol Chem 2012; 393(10): 1141–1150 https://doi.org/10.1515/hsz-2012-0179
33
Hedhli N, Falcone DJ, Huang B, Cesarman-Maus G, Kraemer R, Zhai H, Tsirka SE, Santambrogio L, Hajjar KA. The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol 2012; 2012: 406273
34
Das R, Burke T, Plow EF. Histone H2B as a functionally important plasminogen receptor on macrophages. Blood 2007; 110(10): 3763–3772 https://doi.org/10.1182/blood-2007-03-079392